2026 ACC/AHA Dyslipidemia Guideline Emphasizes Early Intervention and PREVENT-ASCVD
The 2026 ACC/AHA Guideline on Dyslipidemia consolidates evidence-based recommendations, retires the 2018 cholesterol guideline, and stresses earlier lifestyle measures from childhood along with earlier pharmacotherapy for familial hypercholesterolemia and high LDL-C. It also adopts the PREVENT-ASCVD risk equations to guide lipid-lowering therapy in adults aged 30–79, aiming to improve ASCVD prevention.